论文部分内容阅读
目的:观察长春瑞滨与顺铂(NP)方案联合重组人血管内皮抑制素(恩度)治疗老年非小细胞肺癌(NSCLC)的疗效和不良反应。方法:老年NSCLC40例,分为2组:单纯化疗组20例,化疗联合恩度组20例。对近期疗效及不良反应进行评价。结果:单纯化疗组为50.00%(10/20),化疗联合恩度组客观有效率(RR)为55.00%(11/20),两组之间RR的差异显著(P<0.05)。单纯化疗组白细胞下降Ⅲ、Ⅳ度发生率为2.5%,血小板下降Ⅲ、Ⅳ度发生率为0.00%;恩度联合化疗组白细胞下降Ⅲ、Ⅳ度发生率为2.50%,血小板下降Ⅲ、Ⅳ度发生率为0.00%,2组比较差异无显著性(P>0.05)。单纯化疗组消化道症状发生率为80.00%,主要为Ⅰ度;化疗联合恩度组消化道症状发生率为80.00%,主要为I度。结论:NP方案联合恩度治疗老年NSCLC患者,有一定的近期疗效,不良反应与单用NP方案相似。
OBJECTIVE: To observe the efficacy and adverse reactions of vinorelbine and cisplatin (NP) regimens combined with recombinant human endostatin (Endo) in elderly patients with non-small cell lung cancer (NSCLC). Methods: Forty elderly NSCLC patients were divided into two groups: 20 cases of chemotherapy alone group and 20 cases of chemotherapy combined with Endo group. The short-term efficacy and adverse reactions were evaluated. Results: The chemotherapy alone group was 50.00% (10/20), and the objective efficacy rate (RR) of the chemotherapy combined with Endo group was 55.00% (11/20). The RR difference between the two groups was significant (P<0.05). In the chemotherapy alone group, the incidence of leukopenia was 3.5% in grades III and IV, and the rate of grade III and grade IV in thrombocytopenia was 0.00%. The degree of leukopenia in grade III and IV was 2.50%, and the platelet decreased in grade III and IV in the combined degree of chemotherapy group. The incidence was 0.00%. There was no significant difference between the two groups (P>0.05). The incidence of gastrointestinal symptoms in the chemotherapy alone group was 80.00%, mainly in the degree I; the incidence of gastrointestinal symptoms in the chemotherapy combined with Endo group was 80.00%, mainly in the degree I. Conclusion: The combination of NP regimen and Endo in the treatment of elderly patients with NSCLC has a certain short-term efficacy. Adverse reactions are similar to those of NP alone.